Novartis Ag (NVS) Current Taxes (2009 - 2025)
Novartis Ag's (NVS) quarterly Current Taxes came in at $2.0 billion in Q4 2025, up 23.14% year-on-year from $1.6 billion in Q4 2024, and down 30.33% quarter-over-quarter from $2.8 billion in Q2 2025.
Novartis Ag (NVS) Current Taxes (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Current Taxes across 15 years of filings, most recently posting $2.0 billion for Q4 2025.
- Current Taxes for Q4 2025 came in at $2.0 billion, up 23.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.0 billion (up 23.14% YoY), and the FY2025 annual result was $2.0 billion, up 23.14% from the prior year.
- Current Taxes came in at $2.0 billion for Q4 2025 at Novartis Ag, down from $2.8 billion in the prior quarter.
- In the past five years, Current Taxes ranged from a high of $2.8 billion in Q2 2025 to a low of -$391.0 million in Q1 2021.
- The 5-year median for Current Taxes is $2.2 billion (2021), against an average of $1.9 billion.
- Across the five-year window, Current Taxes surged 663.18% in 2021 and fell 27.61% in 2024, its largest moves.
- Novartis Ag's Current Taxes stood at $2.4 billion in 2021, then grew by 4.89% to $2.5 billion in 2022, then slipped by 25.27% to $1.9 billion in 2023, then dropped by 15.53% to $1.6 billion in 2024, then rose by 23.14% to $2.0 billion in 2025.
- The last three Current Taxes figures came in at $2.0 billion (Q4 2025), $2.8 billion (Q2 2025), and $1.6 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -748.24 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 1.09 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | - |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 3.95 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.13 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.97 Bn |
| Jun 30, 2025 | 2.83 Bn |
| Dec 31, 2024 | 1.60 Bn |
| Jun 30, 2024 | 1.92 Bn |
| Dec 31, 2023 | 1.89 Bn |
| Sep 30, 2023 | 203.00 Mn |
| Jun 30, 2023 | 2.65 Bn |
| Dec 31, 2022 | 2.53 Bn |
| Jun 30, 2022 | 2.45 Bn |
| Dec 31, 2021 | 2.42 Bn |
| Jun 30, 2021 | 2.37 Bn |
| Mar 31, 2021 | -391.00 Mn |
| Dec 31, 2020 | 2.46 Bn |
| Sep 30, 2020 | -478.00 Mn |
| Jun 30, 2020 | -421.00 Mn |
| Mar 31, 2020 | -448.00 Mn |
| Dec 31, 2019 | 2.19 Bn |
| Sep 30, 2019 | -366.00 Mn |
| Jun 30, 2019 | -797.00 Mn |
| Mar 31, 2019 | -272.00 Mn |